We are pleased to introduce the following speakers at the 5th International Conference on Resveratrol and Health.

 

 

 

Charlotte Ann Mintie

 

cmintie@dermatology.wisc.edu

 

Department of Dermatology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA

Charlotte Ann Mintie is PhD student Nihal Ahmad’s lab, at University of Wisconsin-Madison ― Madison, WI.

 

The title of her PhD project is: “Dietary Grape Powder in the Management of Skin Cancer”. She have 3 publications, and prepared several presentations.

Dr. Scott Boyer,

 

scott.boyer@klaria.com

 

Nutrinovate AB,

Sweden

Scott Boyer is currently Chief Executive Officer of Klaria AB, a Nasdaq-listed Drug Development Company based in Stockholm. Scott has also been Head of Computational Toxicology at the Swedish Toxicological Research Center at the Karolinska Institute, Sweden.  Prior to this he was Global Head of Molecular and Genetic Toxicology and Chief Scientist at AstraZeneca,  Principal Scientist at Pfizer.

Scott received his postdoctoral training in Molecular Toxicology at the Institute for Environmental Medicine, Karolinska Institute. Doctoral dissertation research was done in molecular toxicology at the University of Colorado in Boulder.

Scott Boyer has authored or co-authored over 100 peer-reviewed publications, over 300 published abstracts and six book chapters.

Dr. Karen Brown

 

kb20@leicester.ac.uk

 

Department of Cancer Studies, Leicester Royal Infirmary, University of Leicester, Leicester,

United Kingdom

Karen is Professor of Translational Cancer Research at the University of Leicester, where she leads the multidisciplinary Cancer Chemoprevention Group.

 

Her undergraduate training was in Pharmacy and her PhD was in Pharmaceutical Chemistry and Molecular Toxicology. Her research is focused on the discovery and preclinical development of agents for the prevention of cancer in populations at increased risk, optimizing the translation of these therapies to the clinic and conducting early and late phase trials. Karen is joint lead of the Leicester Experimental Cancer Medicine Centre.

 

She established and is co-Chair of the UK Therapeutic Cancer Prevention Network and represents this Network on the steering group of the Cancer Prevention Europe Consortium. Karen is also currently the President of the UK Environmental Mutagen Society.

Dr. Kuang Yu Chen

 

kychen@rutgers.edu

Chemistry and Chemical Biology, Rutgers University, Piscataway, NJ, USA

 

Dr. Kuang Yu Chen obtained his Ph.D. in chemistry from Yale University, did post-doctoral work at Yale Medical School in pharmacology, became faculty member at Rutgers University. He is now Distinguished Professor of Chemistry and Chemical Biology at Rutgers. He is also an AAAS Fellow and Board of Director member of Confucius Institute at Ruters. His research focuses on hypusine/eIF-5A, polyamines, aging, and nutraceuticals. He is also interested in the application of chemistry in art and archaeology

   

 Dr. Phillip M. Gerk,

 

pmgerk@vcu.edu

 

Virginia Commonwealth University, School of Pharmacy, Department of Pharmaceutics, Richmond, USA

 Dr. Phillip M. Gerk received his Doctor of Pharmacy (Pharm.D.) degree at the University of Illinois at Chicago, then did a clinical research fellowship at Auburn University.  He then attended the University of Kentucky where he received his Ph.D. and stayed to perform postdoctoral research.  He has been a faculty member at Virginia Commonwealth University in the Department of Pharmaceutics since 2004, where he performs his research on drug metabolism, transport, and oral bioavailability of antioxidants.

Dr. Hiroki Hamada,

 

hamada@dls.ous.ac.jp

 

Department of Life Sciences, Faculty of Science, Okayama University of Sciences, 1-1 Ridai-cho, Kita-ku, Okayama 700-0005, Japan

Professor, Department of Life Science, Faculty of Science, Okayama University of Science, Japan.


He received his Ph.D. degree from Hiroshima University in 1987. From 1988 to 1990, he worked as a postdoctoral fellow in Oklahoma State University and Texas A&M University.

 

In 1992, he was promoted to an assistant professor in Okayama University of Science and in 1998, he was appointed as a professor.
His current research involves development of novel biocatalysts including microbes, plants, and algae.

 

Recently, he is interested in glycosylation of biological active compounds using the living cells.

 

 

Dr. Marina K Holz

 

 

marina_holz@nymc.edu

 

New York Medical College; New York, NY, USA

Dr. Marina Holz is the Dean of the Graduate School of Basic Medical Sciences and Professor of Cell Biology and Anatomy at New York Medical College.

 

Dr. Holz received her Ph.D. in Cell and Developmental Biology at Harvard Medical School. Dr. Holz leads laboratory that studies the mechanisms of signaling by hormones and growth factors in breast cancer and lymphangioleiomyomatosis (LAM) — a rare lung disease.

 

Her work spans basic science and clinical applications.

Professor Peter Howe

 

peter.howe@newcastle.edu.au

 

School of Biomedical Sciences and Pharmacy, The University of Newcastle

Australia

Peter is Professor of Clinical Nutrition at the University of Southern Queensland, Emeritus Professor of Nutrition Research and convenor of the Clinical Nutrition Research Centre, University of Newcastle, Adjunct Professor at the University of South Australia and the University of Adelaide and Chair of TGA’s Advisory Committee for Complementary Medicines.

 

With a track record of preclinical and clinical research in nutrition, cardiovascular physiology and neuroscience, Peter is a recognised authority on health benefits of bioactive nutrients. He is Founding and Emeritus Editor of Nutrients and a Fellow of the Nutrition Society of Australia.

   
   

Dr. Haishu Lin,

 

haishu.lin@nus.edu.sg

 

Department of Pharmacy, National University of Singapore, Singapore

Dr. Haishu Lin is an assistant professor from the Department of Pharmacy, National University of Singapore. During the past ten years, his research is well focused on the anti-inflammatory pharmacology, pharmacokinetics, metabolomics and drug delivery system of resveratrol and its dietary / herbal derivatives. Dr. Lin has ~ 50 publications in peer-reviewed journals and serves as an ad hoc reviewer for ~ 50 journals.
 

Dr. Qingyong Ma

 

qyma56@xjtu.edu.cn

 

Department of Hepatobiliary Surgery, First Affiliated Hospital of Xi’an Jiaotong University, 277 West Yanta Road, Xi’an 710061, PR China
 

 

 

 

Mr. Vu Quang Lam

 

quanglamvu1991@gmail.com

 

Department of Internal Medicine, Division of Hematology, Aichi Medical University School of Medicine,

Nagakute, Aichi, Japan,  1-1 Yazakokarimata, Nagakute, Japan 480-1195

 

 

Vu Quang Lam graduated from the Hanoi University of Science, Vietnam and is currently a Ph.D. candidate at the Division of Hematology, Department of Internal Medicine, Aichi Medical University in Nagakute, Japan. His research work includes studies on the therapeutic utility of resveratrol derivatives for the treatment of blood cancers, specifically on agents capable of enhancing the endogenous immune function of the host to fight cancer cells.

 

His previous scientific work was oriented to the identification of driving mutations in acute myeloid leukemia and the elucidation of cell signals pathways altered in leukemia cells as a consequence of those mutations and that are involved in the pathogenesis of this malignancy.

Dr. Fabricio Medina-Bolivar,

 

fmedinabolivar@astate.edu

 

Plant Metabolic Engineering

Department of Biological Sciences, Arkansas Biosciences Institute, Arkansas State University, AR 72467, USA

Dr. Fabricio Medina-Bolivar is a Professor of Metabolic Engineering at Arkansas State University.  He also serves as Executive Director of the American Council for Medicinally Active Plants and Chief Scientific Officer of Nature West Inc.

 

He has over 25 years of experience in plant biotechnology. Over the last years, his research has focused on bioproduction and biosynthesis of prenylated stilbenoids in hairy root cultures and assessing the biological activities of these compounds. His research led to the identification of the first stilbenoid-specific prenyltransferase involved in the prenylation of resveratrol.

   
   
 

Dr. Thomas Netticadan

 

TNetticadan@sbrc.ca

 

Heart Failure Research Laboratory, Canadian Centre for Agri-Food Research in Health and Medicine, St. Boniface Research Centre, Winnipeg, MB, Canada

Dr. Thomas Netticadan is a Principal Investigator at the Canadian Centre for Agri-Food Research in Health and Medicine, and a Research Scientist with Agriculture and Agri-Food Canada. His research program examines the potential of food-derived compounds in preventing the development of heart failure.

 

For more than a decade, Dr. Netticadan’s group has studied the cardiovascular benefits of polyphenols and fatty acids.


Dr. Coral Sanfeliu Pujol

 

coral.sanfeliu@iibb.csic.es

 

Department  of  Brain  Ischemia  and Neurodegeneration, Institut d’Investigacions Biomèd

iques de Barcelona (IIBB), CSIC-IDIBAPS, Barcelona, Spain

Dr. Coral Sanfeliu is a neuroscientist at the Institute of Biomedical Research of Barcelona (IIBB) of the Spanish research council (CSIC), and also joins IDIBAPS, CIBERESP and European COST networks.

 

She heads the Aging and Neurodegeneration Lab focused in molecular alterations that lead to dementia and in preventive strategies. They are currently investigating endogenous neuroprotective mechanisms induced by resveratrol in experimental models.

   

Dr. Jeff A. Stuart

 

jstuart@brocku.ca

 

Department of Biological Sciences and Cold Climate Oenology and Viticulture Institute, Brock University, St. Catharines, ON L2S 3A1, Canada

Dr. Jeff Stuart received his PhD from the University of Guelph, Canada, followed by postdoctoral research in the Biochemistry Department at the University of Cambridge and at the National Institute on Aging (NIH). 

 

He has been a faculty member at Brock University, Canada, in the Department of Biological Sciences since 2004 and a research fellow at the Cold Climate Oenology and Viticulture Institute at Brock since 2010.  Dr. Stuart’s resveratrol research focuses on its modulation of mitochondrial and cellular functions, including reactive oxygen species metabolism and mitochondrial dynamics.

 

Dr. Tomasz Szkudelski

 

tszkudel@up.poznan.pl

 

Department of Animal Physiology and Biochemistry, Poznan University of Life Sciences, Poznan, Poland

 

Main scientific interests involve studies addressing experimental diabetes in the rat, mechanism of action of diabetogenic agents (alloxan and streptozotocin), and also effect of some naturally-occurring compounds (such as myo-inositol and resveratrol) on metabolic processes and hormone secretion and action.

 

Moreover, regulation of insulin secretion by physiological and pharmacological agents. Studies in vitro (isolated pancreatic islets, perfused pancreas, adipocytes) and in vivo (animal models).

   

 

Dr. Dianzheng Zhang

 

dianzhengzh@pcom.edu

 

Department of Bio-Medical Sciences and Center for Chronic Diseases of Aging, Philadelphia College of Osteopathic Medicine, PA 19131, Philadelphia, USA

 

 

Hold a Ph.D. degree in Nutritional Sciences (University of Arizona). Engaging in research with nutrients/ natural products and cancer thereafter. Focusing on the roles of resveratrol in prostate cancerDeciphering regulating roles of resveratrol on androgen receptor (AR) and AR variants.

 

Resveratrol2018 - resveratrolconference@gmail.com

International Academic Center, Third Floor of Science and Education Building,

The First Affiliated Hospital of Xi’an Jiaotong University, 277 West Yanta Rd, Xi’an, Shaanxi, China.